Nautilus Biotechnology, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Nautilus Q3 2022 earnings call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1-1 on your telephone. I would now like to turn the call over to your host, Alex Khan, Investor Relations. You may begin.

Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30, 2022. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you the manager will make statements today during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled forward-looking statements in the press release Modelist issued today. Except as required by law, Modelist disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as it's live broadcast November 1st, 2022. With that, I'll turn the call over to Sujal.

Thanks, Alex. Good morning, and thank you to everyone for joining us today. On this call, we'll share our results for the third quarter of 2022 and provide some insight on the expected value of our platform, our progress towards commercialization, and a quick observation on the market landscape. But first, I want to thank our growing teams in the Bay Area and Seattle for their focus on short-term development milestones and longer-term commercialization goals. Their efforts continue to yield results that get us ever closer to our ultimate purpose of improving the lives and health of people around the world. Our entire team is fully aligned towards and committed to realizing this important objective. I'm very excited about the emerging opportunity I see for proteomics and I'm pleased with the progress we're making as a business. We, more than ever, envision powerful research uses for our platform and continue to receive enthusiastic feedback from those researchers around the world with whom we've engaged. They consistently tell us their desire to explore the proteome more deeply and their frustration with what's available today. They recognize the inherent limitations of both traditional analysis methods and of emerging affinity-based and peptide sequencing methods. They also understand how important single molecule intact protein analysis and the resulting sensitivity and dynamic range that our platform is designed to deliver will be to their explorations of the proteome. We, and they, foresee a day when an ability to explore the entire proteome more thoroughly will yield fundamental advances in basic biological research, enabling researchers to make a substantial and long-desired impact on the efficiency and cost effectiveness of therapeutic development. Similarly, we believe the next generation of diagnostics will be driven by our ability to measure a patient's proteome with the comprehensiveness that's accessible today in genomics. by designing technologies that measure how our proteins are functioning at any point in time. For example, in healthy versus disease states, physicians, researchers, and epidemiologists will be able to monitor populations for a wide range of conditions and open the gates to methods of precision medicine long dreamed of. Imagine if we could spot a potential viral invader traveling through our bodies and watch our cells interact, change, and shift during times of health and sickness. Through proteomic tests that measure a patient's current state against a previously measured baseline, approaches to personalized and predictive medicine for cancer, heart disease, Alzheimer's disease, and other common illnesses could be made possible. When richer proteomic data begins to drive deeper research insights, we will see a significant increase in patient wellbeing and health. And as I said earlier, at the end of the day, That's why Nautilus exists in the first place. Before I turn the call over to Parag for an update on our development progress, I want to briefly share that, in my view, we are in the very early stages of the journey to fully maximize the potential of the proteome to impact human health. If the decades it took for the genomics market to mature are any indication, there remains much value to be created in the market that will feature multiple complementary participants. Nautilus, we remain heads down, methodically innovating what we believe will be a game-changing platform that will make a meaningful difference for researchers and patients alike in the years and decades to come. With that said, I'll now turn the call over to Parag for an update on our development progress in Q3.